Veridix AI Introduces Protocol Digitization to Streamline Clinical Trial Study Builds
Veridix AI, a subsidiary of the Emmes Group, has unveiled its latest technological advancement aimed at enhancing the efficiency of clinical trials through protocol digitization. Integrated within the company's eClinical platform, Advantage eClinical Cloud, this new capability leverages natural language processing (NLP) and artificial intelligence (AI) to convert unstructured clinical trial protocols into structured data elements. These elements include critical components such as visit schedules, cohort definitions, and electronic case report forms (eCRFs).
The protocol digitization process is designed to automate the traditionally manual and error-prone steps involved in clinical trial study builds. By extracting and structuring data directly from the text of trial protocols, the system enables the automatic generation of visit schedules and predictive lists of eCRFs with an accuracy rate exceeding 82%. This automation promises to reduce the time required to build study databases by up to 30%, according to Veridix AI.
See also: The Rise of Decentralized Clinical Trials: 10 Companies Pushing the Field Forward
The new technology has already been implemented in over 40 study builds within Emmes Group’s portfolio, spanning both governmental and commercial projects. The broader deployment of this capability marks a shift towards the integration of AI in clinical research, potentially improving data quality and accelerating trial timelines.
Future developments for Advantage eClinical Cloud include the ability to automate the construction of eCRFs and associated edit checks based on AI-driven predictions, further streamlining the clinical trial process.
Veridix AI's CEO, Rama Kondru, emphasized the transformative potential of this technology in automating more aspects of the clinical trial process:
"This unique capability allows us to accelerate the study build process and allows our data managers to focus on value added work rather than manual, tedious processes; We're already deploying this capability across more than 40 new study builds in both our government and commercial portfolio; This highlights our commitment to improving clinical trials by applying next generation technology and AI capabilities."
